burantCharles F. Burant, M.D., Ph.D.

Robert C. and Veronica Atkins Professor of Metabolism

Professor of Internal Medicine and Molecular and Integrative Physiology

Director, U-M Metabolomics and Obesity Center

New Approaches in Understanding and Treating Obesity

One of the most basic functions of organisms is to consume, store and then mobilize the energy required to perform work, and these processes are influenced by a wide variety of factors — from a person’s genes to societal forces. An imbalance in nutrient intake and energy expenditure results in weight gain and obesity. Despite a constant barrage of medical recommendations for dietary and behavioral changes and the desire of most people to lose weight, the majority of people attempting to battle obesity are unsuccessful.

Charles Burant and his team are taking advantage of technological advances that have made biological, chemical, behavioral and imaging tools readily available to study an individual’s response to nutrition. Their efforts are focused on understanding biological adaptations to weight loss. By collecting large amounts of data from studies in animals and humans and by using computational tools to integrate and analyze the data, a more complete picture of the metabolic changes associated with obesity and weight loss can be obtained.

Burant’s research utilizes metabolomics — the measurement of small molecules (metabolites) in biological samples. He has begun studies of metabolites in the blood of people before and after weight loss from bariatric surgery (the most successful weight loss method), comparing the changes to those found in people who have lost weight through dieting to give clues as to why surgery is more successful.

By combining the results of metabolomic analysis with other changes in metabolism and behavior, such as appetite, Burant hopes to understand what metabolites might more effectively signal the brain that an individual has eaten enough. This knowledge could provide better ways to change diets or lead to safer and more effective medications to reduce weight.

 


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift

Connect/
Share/
follow/

Follow Us / Friend Us

Discovery-driven research that matters

phallodin

Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding

 

The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more


Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  

Watch the Video